OBJECTIVE： To observe the clinical efficacy and safety of Aidi injection combined with TP regimen in the treatment of non-small cell lung cancer. METHODS： 62 patients with non-small cell lung cancer were randomly divided into control group and observation group， 31 cases in each group. Control group received TP regimen alone， observation group additionally received 40 ml Aidi injection， dissolved in 500 ml 0.9％ Sodium chloride injection by intravenous infusion. 21 d was a treatment course， and it lasted 4 courses. The level of inflammatory cytokines before and after treatment and post-treatment quality of life， short-term efficacy， patients’ satisfaction and toxicity reactions in 2 groups were compared. RESULTS： After treatment， the level of inflammatory cytokines in 2 groups were significantly lower than before， and observation group was lower than control group， the differences were statistically significant （P＜0.05）. The effective rate of life quality （80.64％） and short-term efficacy （83.87％） in observation group significant were higher than control group （32.25％， 64.52％， respectively）， the differences were statistically significant （P＜0.05）. Satisfaction degree （96.77％） in observation group was significantly higher than control group （77.42％）； and the incidences of thrombocytopenia， leukopenia， abnormal liver function were significantly lower than control group， the differences were statistically significant （P＜0.05）. CONCLUSIONS： Aidi injection combined with TP regimen shows good efficacy and little toxicity in the treatment of non-small cell lung cancer， and it helps to reduce the level of inflammatory cytokines in patients， improving immune function and the quality of life of patients.